中国生物科技服务与多家保险公司签署BNCT保险合作备忘录

财中社2025-07-11

7月11日，中国生物科技服务（08037）发布公告，宣布与AXA安盛香港、安盛环球再保险、前海再保险及安睿嘉尔签署了一份不具法律约束力的谅解备忘录，旨在共同开发覆盖硼中子治疗（BNCT）治疗费用及相关服务的普惠型医疗保险产品。此次合作的主要目标是降低患者的经济负担，提高治疗的可及性。在此次合作中，公司将作为BNCT治疗服务及相关第三方理赔管理服务的提供者，而AXA安盛香港将负责香港地区的直保业务，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550772670?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-11 09:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550772670","market":"us","top_or_hot":-1,"title":"中国生物科技服务与多家保险公司签署BNCT保险合作备忘录","media":"财中社","content":"<div>\n<p>7月11日，中国生物科技服务（08037）发布公告，宣布与AXA安盛香港、安盛环球再保险、前海再保险及安睿嘉尔签署了一份不具法律约束力的谅解备忘录，旨在共同开发覆盖硼中子治疗（BNCT）治疗费用及相关服务的普惠型医疗保险产品。此次合作的主要目标是降低患者的经济负担，提高治疗的可及性。在此次合作中，公司将作为BNCT治疗服务及相关第三方理赔管理服务的提供者，而AXA安盛香港将负责香港地区的直保业务，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711090211953e12be&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物科技服务与多家保险公司签署BNCT保险合作备忘录</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物科技服务与多家保险公司签署BNCT保险合作备忘录\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-11 09:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711090211953e12be&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月11日，中国生物科技服务（08037）发布公告，宣布与AXA安盛香港、安盛环球再保险、前海再保险及安睿嘉尔签署了一份不具法律约束力的谅解备忘录，旨在共同开发覆盖硼中子治疗（BNCT）治疗费用及相关服务的普惠型医疗保险产品。此次合作的主要目标是降低患者的经济负担，提高治疗的可及性。在此次合作中，公司将作为BNCT治疗服务及相关第三方理赔管理服务的提供者，而AXA安盛香港将负责香港地区的直保业务，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711090211953e12be&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0240878834.USD","symbol_name":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711090211953e12be&s=b","article_id":"2550772670","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711090211953e12be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550772670","pubTimestamp":1752195674,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"7月11日，中国生物科技服务发布公告，宣布与AXA安盛香港、安盛环球再保险、前海再保险及安睿嘉尔签署了一份不具法律约束力的谅解备忘录，旨在共同开发覆盖硼中子治疗治疗费用及相关服务的普惠型医疗保险产品。通过与领先的保险及再保险公司合作，公司希望借助其在BNCT市场的领导地位和合作伙伴的广泛网络，为更多中国及海外患者提供BNCT治疗。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0240878834.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" (USD) INC AV","LU0054578231.USD":"BGF SYSTEMATIC SUSTAINABLE GLOBAL SMALLCAP \"A2\" (USD) ACC","BK4019":"再保险","LU0240877869.USD":"SCHRODER ISF GLOBAL SMALL COMPANIES \"A\" ACC","RGA":"美国再保险集团","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"China Biotechnology Services signed BNCT insurance cooperation memorandum with a number of insurance companies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGA":0.9},"content_text":"7月11日，中国生物科技服务（08037）发布公告，宣布与AXA安盛香港、安盛环球再保险、前海再保险及安睿嘉尔签署了一份不具法律约束力的谅解备忘录，旨在共同开发覆盖硼中子治疗（BNCT）治疗费用及相关服务的普惠型医疗保险产品。此次合作的主要目标是降低患者的经济负担，提高治疗的可及性。在此次合作中，公司将作为BNCT治疗服务及相关第三方理赔管理服务的提供者，而AXA安盛香港将负责香港地区的直保业务，安盛环球再保险和前海再保险则为再保险公司，安睿嘉尔则担任再保险经纪公司。各方将协助开发具有市场竞争力的BNCT保险产品，并在中国大陆、香港及其他潜在海外市场进行推广。通过与领先的保险及再保险公司合作，公司希望借助其在BNCT市场的领导地位和合作伙伴的广泛网络，为更多中国及海外患者提供BNCT治疗。这一合作突显了公司长期以来致力于推动BNCT治疗和改善全球患者治疗效果的承诺。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550772670","isCrawlerRequest":true}